Neutralizing monoclonal antibodies against PD-1 or PD-L1 have transformed the therapeutic landscape of a wide range of cancers (Table 1), being particularly successful for tumors with limited therapeutic options such as melanoma or lung cancer (3). This evidence concerns the gene CD274 and cancer.